BioSpark聊biotech news：2024年四月生物医药大事讨论 | 药时代直播间

立即预约直播 BioSpark聊biotech news：2024年四月生物医药大事讨论 | 药时代直播间

汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。

本月热点

TOPICS

1. Oncology:

Gritstone Bio’s phase 2 cancer vaccine trial missed the primary endpoint in front-line MSS-CRC;
ParrBio/Syncromune HP007(CpG) plus antibody cocktail in prostate cancer (84.6% ORR);
Macrogenic B7-H3-ADC phase II results;
Profound Bio acquisition by Genmab;
Arvinas/Novartis transaction in Androgen Receptor Degrader for Prostate Cancer;
ImmunityBio’s IL-15 receptor agonist was approved for BCG-unresponsive non-muscle invasive bladder cancer;
FDA Grants Accelerated Approval to Ojemda for Pediatric Relapsed/Refractory BRAF+ Low-Grade Glioma;

2. Autoimmune:

Alpine acquisition by Vertex (and more about TACI);
Nkarta prioritizing CAR-NK therapy for autoimmune diseases and closed $240M PIPE;
Cullinan Therapeutics announced strategic expansion into autoimmune diseases and closed $280 PIPE;

3. Metabolic:

Eli Lilly/Regeneron GLP1/Leptin R agonist combo phase II trial for obesity;

4. CNS:

Sanofi’s frexalimab showed promising efficacy signal in phase 2 trial of multiple sclerosis;
Intra-Cellular Therapies’ Caplyta scored another positive Ph3 readout in major depression disorder, poised to expand its label beyond schizophrenia and bipolar disorder;

5. 其它:

Abbvie/Medincell link up in long-lasting injectable therapies;
NYT and The Economist published articles to highlight the potential negative impact of Biosecure Act that target China CDMO like WuXi AppTec and WuXi Biologics.

活动详情

主题：Monthly biotech news discussion -April 2024 in review

时间：2024年04月26日 Fri 9:00 PM（EST）/ 2024年04月27日周六早上9:00 AM（北京时间）

地点：药时代视频号

嘉宾：

Jimmy Wang(王俊), Assistant Professor @ New York University

(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)

Yanran He(何嫣然), Investment Director @ Sinopharm-CICC

(https://www.linkedin.cn/injobs/in/yanranhe)

Ethan Xu(徐亦迅), VP of Bioinformatics @ Aspen Neuroscience

(http://linkedin.com/in/ethan-yixun-xu-2b915a4)

Stephen Yan(严顺飞), BD Search & Evaluation @ AstraZeneca

(https://www.linkedin.com/in/shunfei-yan/)

Qinghong Yan(晏庆红), CSO @ Leverna Therapeutics

(http://linkedin.com/in/qinghong-yan)

Leon ‘Jun’ TANG(唐钧), Founding Partner @ InScienceWeTrust BioAdvisory

(https://www.linkedin.com/in/leontangnyc/)

Haoran Wang(王浩然), CEO @ Weihai Neoland Biosciences Co.,Ltd.

(https://www.linkedin.com/in/hao-ran-wang-228648b)

Lihua Yu(于利华), Chief Data Officer @ fogpharma

(https://www.linkedin.com/in/lihua-yu-5b3337)

Xianbo Zhou(周显波), Founder & CEO @ AstraNeura

(https://www.linkedin.com/in/xianbo-zhou-7b33b76/)

Charlene Liao (廖晓伶), CEO @ Immune-Onc Therapeutics, Inc. (http://linkedin.com/in/charlene-liao-a1872a55)

Yongjiang Hei(黑永疆), Co-CEO @ Biocity Biopharma

( http://linkedin.com/in/yonghei)

Wenjun Wu(Armstrong,吴文君), Director @ HanKang Venture

(https://www.linkedin.com/in/文君-吴-14787b95/)

本期活动组织：Jun Wang

本月热点总结：Armstrong和monthly news嘉宾

活动直播伙伴

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

成为BioSpark会员：BioSpark期待您的加入–会员推荐与申请

https://www.biospark.org/

Follow us on Twitter:
https://twitter.com/BioSpark_Group

Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar:
https://tinyurl.com/tcwy44t6

Email us: info@BioSpark.org

合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group